Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation With DOJ
Executive SummaryRising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
You may also be interested in...
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
Judge allows plaintiffs to argue attendance at trade association meetings and job-hopping show scheme to fix drug prices; confidentiality of attorney communication is in dispute.
Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.